Cambria Investment Management’s Charles River Laboratories CRL Stock Holding History

Cambria Investment Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$256K	Buy	+1,131	New	+$201K	0.01%	680

Other funds holding CRL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Cambria Investment Management's CRL Position: Q2 2026 in Review

Cambria Investment Management opened a new position in Charles River Laboratories (CRL) in Q2 2026: 1,131 shares worth $256K. The stake represents 0.01% of the portfolio and ranks #680 among its holdings.

563 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Cambria Investment Management held 1,131 shares of Charles River Laboratories worth $256K as of Q2 2026.
Charles River Laboratories was a new Cambria Investment Management position in Q2 2026.
Charles River Laboratories made up 0.01% of Cambria Investment Management's portfolio in Q2 2026, its #680 holding.
563 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Cambria Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.